Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05596708
Other study ID # SZNK
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 1, 2023
Est. completion date September 30, 2026

Study information

Verified date October 2022
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: - To evaluate the clinical efficacy of Telitacicept in patients with refractory IgA nephropathy. - To evaluate the safety and adverse reaction of Telitacicept in patients with refractory IgA nephropathy. Participants will be subcutaneously injected with 240mg of Telitacicept once per week. Study subject: After 6 months of sequential treatment with renin-angiotensin system (RAS) blockers or glucocorticoids, patients with pathological biopsy of 0.7≥5 g/24 hours of proteinuria was confirmed as refractory IgA nephropathy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date September 30, 2026
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign the informed consent form. 2. IgA nephropathy was confirmed by pathological biopsy. 3. Age range: = 18 years old, = 70 years old, male or female. 4. During the screening period, the 24-hour urine protein of Visit 1 and Visit 2 should meet at least one =0.75g/24h, and the 24-hour urine protein = 0.75g/24h at Visit 3. 5. Measured glomerular filtration rate or estimated GFR (using the CKD-EPI formula) > 35 mL/min/1.73 m2. 6. Participants had received a basic regimen including ACE inhibitors/ARBs for 12 weeks prior to randomization, and the dose of ACE inhibitors/ARBs (within the maximum tolerated range) was stable for 4 weeks prior to randomization. Exclusion Criteria: 1. Abnormal laboratory indicators of participants need to be excluded. 2. Secondary IgA nephropathy need to be excluded. 3. Specific pathologic or clinical renal disease types, and IgA nephropathy that may require hormone therapy. 4. Patients who have experienced any of the following cardiovascular and cerebrovascular events within the 12 weeks prior to screening. 5. Use of systemic corticosteroids within 3 months prior to randomization (except local, nasal inhalation, etc.) 6. Immunosuppressants were used within 3 months prior to randomization. 7. Patients requiring hospitalization for active infection or intravenous anti-infective therapy within 3 months prior to randomization. 8. Previously or currently diagnosed active tuberculosis Untreated latent tuberculosis. 9. Herpes zoster HIV antibody positive or HCV antibody positive during the screening period. 10. Those who currently have active hepatitis or have severe liver disease and medical history. 11. Patients with malignant tumors. 12. Pregnant and lactating women, and men or women with planned children during the trial period. 13. Those who could not avoid the use of nephrotoxic drugs during the trial. 14. Allergic to human biological products. 15. Patients who have been given any of the clinical trial drugs 4 weeks prior to randomization or within 5 times the half-life of the experimental drug (whichever is longer). 16. Patients deemed ineligible for the trial by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Telitacicept
Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.

Locations

Country Name City State
China The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete clinical response a. Proteinuria: protein-to-creatinine ratio <0.2; b. Stable renal function: eGFR decreased by less than 5ml/min/1.73m2 from baseline at the end of the 3-year trial phase. 3-year
Primary The absolute value of eGFR The absolute value of eGFR decreased by more than 15 ml/min/1.73m2 over 3 years from baseline 3-year
Primary Changes in 24-hour urinary protein Changes in 24-hour urinary protein at week 104 compared with baseline. 104 weeks
Secondary eGFR decrease The estimated glomerular filtration rate (eGFR) decreased by more than 30 ml/min/1.73 m2 from baseline. 3-year
Secondary Need for dialysis progression to end-stage renal disease 3-year
See also
  Status Clinical Trial Phase
Recruiting NCT05016323 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. Phase 2
Withdrawn NCT02433236 - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Phase 2
Recruiting NCT02231125 - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Phase 4
Completed NCT01502579 - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data N/A
Not yet recruiting NCT01203007 - Diet Intervention in Food Sensitive Patients With IgA Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00657059 - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Phase 3
Recruiting NCT04684745 - Open-Label Extension Study of BION-1301 in IgA Nephropathy Phase 2
Completed NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects Phase 1
Completed NCT02112838 - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Phase 2
Withdrawn NCT02052219 - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Phase 3
Completed NCT00767221 - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Phase 2
Recruiting NCT04438603 - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Terminated NCT04905212 - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Phase 2
Terminated NCT04042623 - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy Phase 2
Recruiting NCT03633864 - Fecal Microbiota Transplantation for Refractory IgA Nephropathy Phase 2
Not yet recruiting NCT06454110 - Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) Phase 2
Recruiting NCT02954419 - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting NCT03001947 - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)